



Virus-Like Particle Vaccines and Other Vaccine Formulations Against Respiratory Viruses and Protozoan Parasites

Guest Editor:

Prof. Dr. Fu-Shi Quan

1. Department of Medical
Zoology, Kyung Hee University
School of Medicine, Seoul 02447,
Korea
2. Medical Research Center for
Bioreaction to Reactive Oxygen
Species and Biomedical Science
Institute, School of Medicine,
Graduate School, Kyung Hee
University, Seoul 02447, Korea

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editor

Dear Colleagues,

Respiratory viruses (influenza virus, respiratory syncytial virus) and protozoan parasites (*Plasmodium* spp., *Toxoplasma gondii*, *Leishmania* spp.) continue to threaten public health worldwide. Although many efforts have been made to develop vaccines, effective vaccines are currently lacking for many of these pathogens. This Special Issue focuses on the development of vaccines based on virus-like particles and other platforms against respiratory viruses and protozoan parasites. We invite the submission of any original research articles and reviews on vaccine studies, and they will be highly appreciated.

Prof. Dr. Fu-Shi Quan
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com